| Oral selinexor–dexamethasone for triple-class refractory multiple myeloma A Chari, DT Vogl, M Gavriatopoulou, AK Nooka, AJ Yee, CA Huff, ... New England Journal of Medicine 381 (8), 727-738, 2019 | 589 | 2019 |
| Organ-specific manifestations of COVID-19 infection M Gavriatopoulou, E Korompoki, D Fotiou, I Ntanasis-Stathopoulos, ... Clinical and experimental medicine 20, 493-506, 2020 | 522 | 2020 |
| Emerging treatment strategies for COVID-19 infection M Gavriatopoulou, I Ntanasis-Stathopoulos, E Korompoki, D Fotiou, ... Clinical and experimental medicine 21, 167-179, 2021 | 354 | 2021 |
| Pathogenesis of bone disease in multiple myeloma: from bench to bedside E Terpos, I Ntanasis-Stathopoulos, M Gavriatopoulou, MA Dimopoulos Blood cancer journal 8 (1), 7, 2018 | 284 | 2018 |
| Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label … S Grosicki, M Simonova, I Spicka, L Pour, I Kriachok, M Gavriatopoulou, ... The Lancet 396 (10262), 1563-1573, 2020 | 253 | 2020 |
| Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European … MA Dimopoulos, R García-Sanz, M Gavriatopoulou, P Morel, ... Blood, The Journal of the American Society of Hematology 122 (19), 3276-3282, 2013 | 202 | 2013 |
| Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease E Kastritis, E Terpos, L Moulopoulos, M Spyropoulou-Vlachou, ... Leukemia 27 (4), 947-953, 2013 | 201 | 2013 |
| Epidemiology and organ specific sequelae of post-acute COVID19: a narrative review E Korompoki, M Gavriatopoulou, RS Hicklen, I Ntanasis-Stathopoulos, ... Journal of Infection 83 (1), 1-16, 2021 | 173 | 2021 |
| Oncology during the COVID‑19 pandemic: challenges, dilemmas and the psychosocial impact on cancer patients K Tsamakis, M Gavriatopoulou, D Schizas, A Stravodimou, A Mougkou, ... Oncology letters 20 (1), 441-447, 2020 | 168 | 2020 |
| Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors MA Dimopoulos, M Roussou, M Gavriatopoulou, F Zagouri, M Migkou, ... Clinical Lymphoma and Myeloma 9 (4), 302-306, 2009 | 155 | 2009 |
| Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of … MA Dimopoulos, E Kastritis, D Christoulas, M Migkou, M Gavriatopoulou, ... Leukemia 24 (10), 1769-1778, 2010 | 149 | 2010 |
| Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose E Terpos, IP Trougakos, M Gavriatopoulou, I Papassotiriou, AD Sklirou, ... Blood, The Journal of the American Society of Hematology 137 (26), 3674-3676, 2021 | 145 | 2021 |
| Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis E Kastritis, X Leleu, B Arnulf, E Zamagni, MT Cibeira, F Kwok, P Mollee, ... Journal of Clinical Oncology 38 (28), 3252-3260, 2020 | 129 | 2020 |
| Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study E Kastritis, M Gavriatopoulou, MC Kyrtsonis, M Roussou, E Hadjiharissi, ... Blood, The Journal of the American Society of Hematology 126 (11), 1392-1394, 2015 | 128 | 2015 |
| The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment E Terpos, M Gavriatopoulou, I Ntanasis-Stathopoulos, A Briasoulis, ... Blood Cancer Journal 11 (8), 138, 2021 | 122 | 2021 |
| A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis E Kastritis, E Terpos, M Roussou, M Gavriatopoulou, C Pamboukas, ... Blood, The Journal of the American Society of Hematology 119 (23), 5384-5390, 2012 | 119 | 2012 |
| European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias M Gavriatopoulou, P Musto, J Caers, G Merlini, E Kastritis, N van de Donk, ... Leukemia 32 (9), 1883-1898, 2018 | 115 | 2018 |
| Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents M Roussou, E Kastritis, D Christoulas, M Migkou, M Gavriatopoulou, ... Leukemia research 34 (10), 1395-1397, 2010 | 110 | 2010 |
| Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients … LA Moulopoulos, MA Dimopoulos, E Kastritis, D Christoulas, ... American journal of hematology 87 (9), 861-864, 2012 | 105 | 2012 |
| Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a … SZ Usmani, H Quach, MV Mateos, O Landgren, X Leleu, D Siegel, ... The Lancet Oncology 23 (1), 65-76, 2022 | 102 | 2022 |
